Presence of circulating anti-CCL21 antibodies that specifically bind CCL21, and reduce availability of the chemokine for ELISA capture, could potentially explain finding of low CCL21 levels in some SSc patients with PAH. The gene discussed is CCL21; the disease is systemic sclerosis.